NervGen Provides Quarterly “At-The-Market” Equity Program and Grant of Options Update
VANCOUVER, Canada July 7, 2025 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative treatments for spinal cord injury (SCI) and other neurological conditions, today provided a quarterly update with respect to the Company’s previously announced at-the-market equity program (the “ATM Program”) launched on […]
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results of Phase 1b/2a CONNECT SCI Study VANCOUVER, Canada, July 3, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative treatments for spinal cord injury (SCI) and other neurological conditions, […]
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
VANCOUVER, Canada, July 1, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced that Daniel Mikol, MD, Ph.D., has resigned from his position as Chief Medical Officer in order to pursue new opportunities. Randall Kaye, MD, who was recently appointed Chief Medical Advisor, will […]
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Vancouver, Canada, June 18, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Dr. Kaye, a current member of NervGen’s Board of Directors and Chair of the Science Committee since 2020, […]
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord injury (SCI). Study also showed a positive trend in the secondary endpoint evaluating change in “GRASSP” score, a measure designed […]
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
VANCOUVER, Canada, May 21, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that topline results from the chronic cohort of the ongoing Phase 1b/2a study of NVG-291 will be presented as an oral presentation at the 52nd American Spinal Injury Association Annual Scientific […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. May 16, 2025 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that it has granted 600,000 incentive stock options (the “Options”) to directors and employees of the company. The Options are exercisable at a price of $4.00 per share. 500,000 of the […]
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
Completed last subject, last visit in the chronic cohort, data readout targeted for early June 2025 Vancouver, Canada May 15, 2025 – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuro-reparative therapeutics, today reported its financial and operational results for the first quarter ended March 31, 2025. “We […]
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Vancouver, Canada, May 7, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, announces the results of its Annual General Meeting of Shareholders (“AGM”) held on May 6, 2025. The company reports that at the AGM […]
NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, Canada, April 21, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto, ON. Mike Kelly, President & CEO, is scheduled to present at the conference on Monday, May 5, […]